How robust are malaria parasite clearance rates as indicators of drug effectiveness and resistance?

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 10, 2015, Pages 6428-6436

  Hastings, Ian M ^a   Kay, Katherine ^a   Hodel, Eva Maria ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE PLUS MEFLOQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ARTESUNATE; DIHYDROARTEMISININ; DRUG COMBINATION; MEFLOQUINE; PIPERAQUINE; QUINOLINE DERIVATIVE;

ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; DRUG EFFICACY; ERYTHROCYTE; HOST RESISTANCE; HUMAN; MALARIA FALCIPARUM; NONHUMAN; PARASITE CLEARANCE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; ADULT; CHILD; DOSE CALCULATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SENSITIVITY; IMMUNOLOGY; INNATE IMMUNITY; MALARIA, FALCIPARUM; PARASITEMIA; PARASITOLOGY; PHYSIOLOGY; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; ANTIMALARIALS; ARTEMISININS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG DOSAGE CALCULATIONS; DRUG RESISTANCE; HUMANS; IMMUNITY, INNATE; MALARIA, FALCIPARUM; MEFLOQUINE; MODELS, STATISTICAL; PARASITEMIA; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; QUINOLINES; TREATMENT OUTCOME;

EID: 84942865657     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00481-15     Document Type: Article

References (60)

1. World Health Organization. 2010. Guidelines for the treatment of malaria, 2nd ed. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/publications/2010/9789241547925-eng.pdf.
2. Dondorp A, Nosten F, Yi P, Das D, Phyo A, Tarning J, Lwin K, Ariey F, Hanpithakpong W, Lee S, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An S, Yeung S, Singhasivanon P, Day N, Lindegardh N, Socheat D, White N. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361:455-467. http://dx.doi.org/10.1056/NEJMoa0808859.
3. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, Moo CL, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day NPJ, White NJ, Anderson T J C, Nosten F. 2012. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 379:1960-1966. http://dx.doi.org/10.1016/S0140-6736 (12) 60484-X.
4. Amaratunga C, Sreng S, Suon S, Phelps ES, Stepniewska K, Lim P, Zhou C, Mao S, Anderson JM, Lindegardh N, Jiang H, Song J, Su XZ, White NJ, Dondorp AM, Anderson TJC, Fay MP, Mu J, Duong S, Fairhurst RM. 2012. Artemisinin-resistant Plasmodium falciparum in Pursat Province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis 12:851-858. http://dx.doi.org/10.1016/S1473-3099 (12) 70181-0.
5. Miotto O, Almagro-Garcia J, Manske M, MacInnis B, Campino S, Rockett KA, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Duong S, Nguon C, Chuor CM, Saunders D, Se Y, Lon C, Fukuda MM, Amenga-Etego L, Hodgson AVO, Asoala V, Imwong M, Takala-Harrison S, Nosten F, Su X-z, Ringwald P, Ariey F, Dolecek C, Hien TT, Boni MF, Thai CQ, Amambua-Ngwa A, Conway DJ, Djimde AA, Doumbo OK, Zongo I, Ouedraogo J-B, Alcock D, Drury E, Auburn S, Koch O, Sanders M, Hubbart C, Maslen G, Ruano-Rubio V, Jyothi D, Miles A, O'Brien J, Gamble C, Oyola SO, et al. 2013. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet 45:648-655. http://dx.doi.org/10.1038/ng.2624.
6. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, Study C. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359:2619-2620. http://dx.doi.org/10.1056/NEJMc0805011.
7. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, Sopha C, Chuor CM, Nguon C, Sovannaroth S, Pukrittayakamee S, Jittamala P, Chotivanich K, Chutasmit K, Suchatsoonthorn C, Runcharoen R, Hien TT, Thuy-Nhien NT, Thanh NV, Phu NH, Htut Y, Han K-T, Aye KH, Mokuolu OA, Olaosebikan RR, Folaranmi OO, Mayxay M, Khanthavong M, Hongvanthong B, Newton PN, Onyamboko MA, Fanello CI, Tshefu AK, Mishra N, Valecha N, Phyo AP, Nosten F, Yi P, Tripura R, Borrmann S, Bashraheil M, Peshu J, Faiz MA, Ghose A, Hossain MA, Samad R, et al. 2014. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 371:411-423. http://dx.doi.org/10.1056/NEJMoa1314981.
8. Breman JG. 2012. Resistance to artemisinin-based combination therapy. Lancet Infect Dis 12:820-822. http://dx.doi.org/10.1016/S1473-3099 (12) 70226-8.
9. Uhlemann A-C, Fidock DA. 2012. Loss of malarial susceptibility to artemisinin in Thailand. Lancet 379:1928-1930. http://dx.doi.org/10.1016/S0140-6736 (12) 60488-7.
10. Fairhurst RM, Nayyar GML, Breman JG, Hallett R, Vennerstrom JL, Duong S, Ringwald P, Wellems TE, Plowe CV, Dondorp AM. 2012. Artemisinin-resistant malaria: research challenges, opportunities, and public health implications. AmJ Trop Med Hyg 87:231-241. http://dx.doi.org/10.4269/ajtmh.2012.12-0025.
11. Talisuna AO, Karema C, Ogutu B, Juma E, Logedi J, Nyandigisi A, Mulenga M, Mbacham WF, Roper C, Guerin PJ, D'Alessandro U, Snow RW. 2012. Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systems. Lancet Infect Dis 12:888-895. http://dx.doi.org/10.1016/S1473-3099 (12) 70241-4.
12. Dondorp AM, Yeung S, White L, Nguon C, Day NPJ, Socheat D, von Seidlein L. 2010. Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol 8:272-280.
13. World Wide Antimalarial Resistance Network. 2015. Parasite clearance estimator (PCE) WorldWide Antimalarial Resistance Network, Oxford, United Kingdom. http://www.wwarn.org/tools-resources/toolkit/analyse/parasite-clearance-estimator-pce.
14. Das D, Tripura R, Phyo AP, Lwin KM, Tarning J, Lee SJ, Hanpithakpong W, Stepniewska K, Menard D, Ringwald P, Silamut K, Imwong M, Chotivanich K, Yi P, Day NPJ, Lindegardh N, Socheat D, Nguon C, White NJ, Nosten F, Dondorp AM. 2013. Effect of high-dose or splitdose artesunate on parasite clearance in artemisinin-resistant falciparum malaria. Clin Infect Dis 56:e48-e58. http://dx.doi.org/10.1093/cid/cis958.
15. Krishna S, Kremsner PG. 2013. Antidogmatic approaches to artemisinin resistance: reappraisal as treatment failure with artemisinin combination therapy. Trends Parasitol 29:313-317. http://dx.doi.org/10.1016/j.pt.2013.04.001.
16. Ferreira PE, Culleton R, Gil JP, Meshnick SR. 2013. Artemisinin resistance in Plasmodium falciparum: what is it really? Trends Parasitol 29:318-320. http://dx.doi.org/10.1016/j.pt.2013.05.002.
17. Meshnick S. 2012. Perspective: artemisinin-resistant malaria and the wolf. Am J Trop Med Hyg 87:783-784. http://dx.doi.org/10.4269/ajtmh.2012.12-0388.
18. White NJ. 2011. The parasite clearance curve. Malar J 10:278. http://dx.doi.org/10.1186/1475-2875-10-278.
19. Day NPJ, Diep PT, Ly PT, Sinh DX, Loc PP, Van Chuong L, Chau TTH, Mai NTH, Bethell DB, Phu NH, Hien TT, White NJ. 1996. Clearance kinetics of parasites and pigment-containing leukocytes in severe malaria. Blood 88:4694-4700.
20. Flegg JA, Guerin PJ, White NJ, Stepniewska K. 2011. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J 10:339. http://dx.doi.org/10.1186/1475-2875-10-339.
21. Jamsen K, Duffull S, Tarning J, Price R, Simpson J. 2013. A robust design for identification of the parasite clearance estimator. Malar J 12:410. http://dx.doi.org/10.1186/1475-2875-12-410.
22. World Health Organization. 2011. Methods and techniques for assessing exposure to antimalarial drugs in clinical field studies. World Health Organization, Geneva, Switzerland. http://apps.who.int/iris/bitstream/10665/44653/1/9789241502061-eng.pdf.
23. Zaloumis S, Humberstone A, Charman S, Price R, Moehrle J, Gamo-Benito J, McCaw J, Jamsen K, Smith K, Simpson J. 2012. Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development. Malar J 11:303. http://dx.doi.org/10.1186/1475-2875-11-303.
24. Warhurst DC, Williams JE. 1996. Laboratory diagnosis of malaria. J Clin Pathol 49:533-538. http://dx.doi.org/10.1136/jcp. 49.7.533.
25. Kremsner PPG, Krishna PS. 2004. Antimalarial combinations. Lancet 364:285-294. http://dx.doi.org/10.1016/S0140-6736 (04) 16680-4.
26. Watkins WM, Woodrow C, Marsh K. 1993. Falciparum malaria: differential effects of antimalarial drugs on ex vivo parasite viability during the critical early phase of therapy. Am J Trop Med Hyg 49:106-112.
27. Hoshen MB, Na-Bangchang K, Stein WD, Ginsburg H. 2000. Mathematical modelling of the chemotherapy of Plasmodium falciparummalaria with artesunate: postulation of 'dormancy', a partial cytostatic effect of the drug, and its implication for treatment regimens. Parasitology 121:237-246. http://dx.doi.org/10.1017/S0031182099006332.
28. Saralamba S, Pan-Ngum W, Maude RJ, Lee SJ, Tarning J, Lindegårdh N, Chotivanich K, Nosten F, Day NPJ, Socheat D, White NJ, Dondorp AM, White LJ. 2011. Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A 108:397-402. http://dx.doi.org/10.1073/pnas.1006113108.
29. Hietala SF, Mårtensson A, Ngasala B, Dahlström S, Lindegårdh N, Annerberg A, Premji Z, Färnert A, Gil P, Björkman A, Ashton M. 2010. Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania. Antimicrob Agents Chemother 54:4780-4788. http://dx.doi.org/10.1128/AAC.00252-10.
30. Gordi T, Xie R, Jusko WJ. 2005. Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin. Br J Clin Pharmacol 60:594-604. http://dx.doi.org/10.1111/j.1365-2125.2005.02508.x.
31. World Health Organization. 2015. Microscopy for the detection, identification and quantification of malaria parasites on stained thick and thin blood films in research settings. World Health Organization, Geneva, Switzerland. http://www.who.int/tdr/publications/microscopy-detec-ident-quantif/en/.
32. Beshir KB, Sutherland CJ, Sawa P, Drakeley CJ, Okell L, Mweresa CK, Omar SA, Shekalaghe SA, Kaur H, Ndaro A, Chilongola J, Schallig HDFH, Sauerwein RW, Hallett RL, Bousema T. 2013. Residual Plasmodium falciparum parasitemia in Kenyan children after artemisinincombination therapy is associated with increased transmissiontomosquitoes and parasite recurrence. J Infect Dis 208:2017-2024. http://dx.doi.org/10.1093/infdis/jit431.
33. Hastings I, Hodel EM. 2014. Pharmacological considerations in the design of anti-malarial drug combination therapies-is matching half-lives enough? Malar J 13:62. http://dx.doi.org/10.1186/1475-2875-13-62.
34. Kay K, Hodel EM, Hastings IM. 2015. Altering antimalarial drug regimens may dramatically enhance and restore drug effectiveness. Antimicrob Agents Chemother 59:6419-6427. http://dx.doi.org/10.1128/AAC.00482-15.
35. Mok S, Ashley EA, Ferreira PE, Zhu L, Lin Z, Yeo T, Chotivanich K, Imwong M, Pukrittayakamee S, Dhorda M, Nguon C, Lim P, Amaratunga C, Suon S, Hien TT, Htut Y, Faiz MA, Onyamboko MA, Mayxay M, Newton PN, Tripura R, Woodrow CJ, Miotto O, Kwiatkowski DP, Nosten F, Day NPJ, Preiser PR, White NJ, Dondorp AM, Fairhurst RM, Bozdech Z. 2015. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science 347:431-435. http://dx.doi.org/10.1126/science.1260403.
36. Klonis N, Xie SC, McCaw JM, Crespo-Ortiz MP, Zaloumis SG, Simpson JA, Tilley L. 2013. Altered temporal response of malaria parasites determines differential sensitivity toartemisinin. Proc Natl Acad Sci U S A 110:5157-5162. http://dx.doi.org/10.1073/pnas.1217452110.
37. Greenhouse B, Slater M, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi C, Clark TD, Staedke SG, Kamya MR, Hubbard A, Rosenthal PJ, Dorsey G. 2009. Decreasing efficacy of antimalarial combination therapy in Uganda is explained by decreasing host immunity rather than increasing drug resistance. J Infect Dis 199:758-765. http://dx.doi.org/10.1086/596741.
38. Lopera-Mesa TM, Doumbia S, Chiang S, Zeituni AE, Konate DS, Doumbouya M, Keita AS, Stepniewska K, Traore K, Diakite SAS, Ndiaye D, Sa JM, Anderson JM, Fay MP, Long CA, Diakite M, Fairhurst RM. 2013. Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity. J Infect Dis 207:1655-1663. http://dx.doi.org/10.1093/infdis/jit082.
39. Bethell D, Se Y, Lon C, Tyner S, Saunders D, Sriwichai S, Darapiseth S, Teja-Isavadharm P, Khemawoot P, Schaecher K, Ruttvisutinunt W, Lin J, Kuntawungin W, Gosi P, Timmermans A, Smith B, Socheat D, Fukuda MM. 2011. Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial. PLoS One 6:e19283. http://dx.doi.org/10.1371/journal.pone.0019283.
40. Kyaw MP, Nyunt MH, Chit K, Aye MM, Aye KH, Aye MM, Lindegardh N, Tarning J, Imwong M, Jacob CG, Rasmussen C, Perin J, Ringwald P, Nyunt MM. 2013. Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS One 8:e57689. http://dx.doi.org/10.1371/journal.pone.0057689.
41. Stepniewska K, Ashley E, Lee SJ, Anstey N, Barnes KI, Binh TQ, D'Alessandro U, Day NPJ, De Vries PJ, Dorsey G, Guthmann JP, Mayxay M, Newton PN, Olliaro P, Osorio L, Price RN, Rowland M, Smithuis F, Taylor WRJ, Nosten F, White NJ. 2010. In vivo parasitological measures of artemisinin susceptibility. J Infect Dis 201:570-579. http://dx.doi.org/10.1086/650301.
42. Rogerson SJ, Wijesinghe RS, Meshnick SR. 2010. Host immunity as a determinant of treatment outcome in Plasmodium falciparum malaria. Lancet Infect Dis 10:51-59. http://dx.doi.org/10.1016/S1473-3099 (09) 70322-6.
43. Henriques G, Hallett RL, Beshir KB, Gadalla NB, Johnson RE, Burrow R, van Schalkwyk DA, Sawa P, Omar SA, Clark TG, Bousema T, Sutherland CJ. 2014. Directional selection at the pfmdr1, pfcrt, pfubp1, and pfap2mu loci of Plasmodium falciparum in Kenyan children treated with ACT. J Infect Dis 210:2001-2008. http://dx.doi.org/10.1093/infdis/jiu358.
44. Wootton DG, Opara H, Biagini GA, Kanjala MK, Duparc S, Kirby PL, Woessner M, Neate C, Nyirenda M, Blencowe H, Dube-Mbeye Q, Kanyok T, Ward S, Molyneux M, Dunyo S, Winstanley PA. 2008. Open-label comparative clinical study of chlorproguanil-dapsone fixed dose combination (Lapdap) alone or with three different doses of artesunate for uncomplicated Plasmodium falciparum malaria. PLoS One 3:e1779. http://dx.doi.org/10.1371/journal.pone.0001779.
45. Winter K, Hastings IM. 2011. Development, evaluation and application of an in silico model for antimalarial drug treatment and failure. Antimicrob Agents Chemother 55:3380-3392. http://dx.doi.org/10.1128/AAC.01712-10.
46. Kay K, Hastings IM. 2013. Improving pharmacokinetic-pharmacodynamic modeling to investigate anti-infective chemotherapy with application to the current generation of antimalarial drugs. PLoS Comput Biol 9:e1003151. http://dx.doi.org/10.1371/journal.pcbi.1003151.
47. Angus BJ, Thaiaporn I, Chanthapadith K, Suputtamongkol Y, White NJ. 2002. Oral artesunate dose-response relationship in acute falciparum malaria. Antimicrob Agents Chemother 46:778-782. http://dx.doi.org/10.1128/AAC.46.3.778-782.2002.
48. Saunders D, Khemawoot P, Vanachayangkul P, Siripokasupkul R, Bethell D, Tyner S, Se Y, Rutvisuttinunt W, Sriwichai S, Chanthap L, Lin J, Timmermans A, Socheat D, Ringwald P, Noedl H, Smith B, Fukuda M, Teja-Isavadharm P. 2012. Pharmacokinetics and pharmacodynamics of oral artesunate monotherapy in patients with uncomplicated Plasmodium falciparum malaria in western Cambodia. Antimicrob Agents Chemother 56:5484-5493. http://dx.doi.org/10.1128/AAC.00044-12.
49. Greenwood B. 2014. Treatment of malaria-a continuing challenge. N Engl J Med 371:474-475. http://dx.doi.org/10.1056/NEJMe1407026.
50. Spring MD, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R, Se Y, Chann S, Ittiverakul M, Sia-ngam P, Kuntawunginn W, Arsanok M, Buathong N, Chaorattanakawee S, Gosi P, Ta-aksorn W, Chanarat N, Sundrakes S, Kong N, Heng TK, Nou S, Teja-isavadharm P, Pichyangkul S, Phann ST, Balasubramanian S, Juliano JJ, Meshnick SR, Chour CM, Prom S, Lanteri CA, Lon C, Saunders DL. 2015. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis 15:683-691. http://dx.doi.org/10.1016/S1473-3099 (15) 70049-6.
51. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor CM, Bout DM, Menard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale J-C, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Menard D. 2014. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505:50-55.
52. Dondorp AM, Ringwald P. 2013. Artemisinin resistance is a clear and present danger. Trends Parasitol 29:359-360. http://dx.doi.org/10.1016/j.pt.2013.05.005.
53. Krishna S, Kremsner PG. 2013. Artemisinin resistance needs to be defined rigorously to be understood: response to Dondorp and Ringwald. Trends Parasitol 29:361-362. http://dx.doi.org/10.1016/j.pt.2013.05.006.
54. Straimer J, Gnädig NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP, Dacheux M, Khim N, Zhang L, Lam S, Gregory PD, Urnov FD, Mercereau-Puijalon O, Benoit-Vical F, Fairhurst RM, Ménard D, Fidock DA. 2015. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science 347:428-431. http://dx.doi.org/10.1126/science.1260867.
55. Hunt P, Afonso A, Creasey A, Culleton R, Sidhu ABS, Logan J, Valderramos SG, McNae I, Cheesman S, Rosario Vd, Carter R, Fidock DA, Cravo P. 2007. Gene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquine-resistant rodent malaria parasites. Mol Microbiol 65:27-40. http://dx.doi.org/10.1111/j.1365-2958.2007.05753.x.
56. Henriques G, van Schalkwyk DA, Burrow R, Warhurst DC, Thompson E, Baker DA, Fidock DA, Hallett R, Flueck C, Sutherland CJ. 2015. The mu subunit of Plasmodium falciparumclathrin-associated adaptor protein 2 modulates in vitro parasite response to artemisinin and quinine. Antimicrob Agents Chemother 59:2540-2547. http://dx.doi.org/10.1128/AAC.04067-14.
57. Plowe CV. 2014. Malaria: resistance nailed. Nature 505:30-31.
58. Anderson T, Nkhoma S, Ecker A, Fidock D. 2011. How can we identify parasite genes that underlie antimalarial drug resistance? Pharmacogenomics 12:59-85. http://dx.doi.org/10.2217/pgs.10.165.
59. Mwangi JM, Ranford-Cartwright LC. 2013. Genetic and genomic approaches for the discovery of parasite genes involved in antimalarial drug resistance. Parasitology 140:1455-1467. http://dx.doi.org/10.1017/S0031182013000954.
60. World Health Organization. 2011. Global plan for artemisinin resistance containment. World Health Organization, Geneva, Switzerland. http://www.who.int/malaria/publications/atoz/artemisinin-resistance-containment-2011.pdf.